DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Mosaic protein and nucleic acid vaccines against hepatitis C virus

Abstract

The invention relates to immunogenic compositions useful as HCV vaccines. Provided are HCV mosaic polypeptide and nucleic acid compositions which provide higher levels of T-cell epitope coverage while minimizing the occurrence of unnatural and rare epitopes compared to natural HCV polypeptides and consensus HCV sequences.

Inventors:
; ; ;
Issue Date:
Research Org.:
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1084254
Patent Number(s):
8460672
Application Number:
12/893,731
Assignee:
Los Alamos National Security, LLC (Los Alamos, NM)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C12 - BIOCHEMISTRY C12N - MICROORGANISMS OR ENZYMES
DOE Contract Number:  
AC52-06 NA 25396
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Yusim, Karina, Korber, Bette T. M., Kuiken, Carla L., and Fischer, William M. Mosaic protein and nucleic acid vaccines against hepatitis C virus. United States: N. p., 2013. Web.
Yusim, Karina, Korber, Bette T. M., Kuiken, Carla L., & Fischer, William M. Mosaic protein and nucleic acid vaccines against hepatitis C virus. United States.
Yusim, Karina, Korber, Bette T. M., Kuiken, Carla L., and Fischer, William M. Tue . "Mosaic protein and nucleic acid vaccines against hepatitis C virus". United States. https://www.osti.gov/servlets/purl/1084254.
@article{osti_1084254,
title = {Mosaic protein and nucleic acid vaccines against hepatitis C virus},
author = {Yusim, Karina and Korber, Bette T. M. and Kuiken, Carla L. and Fischer, William M.},
abstractNote = {The invention relates to immunogenic compositions useful as HCV vaccines. Provided are HCV mosaic polypeptide and nucleic acid compositions which provide higher levels of T-cell epitope coverage while minimizing the occurrence of unnatural and rare epitopes compared to natural HCV polypeptides and consensus HCV sequences.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Jun 11 00:00:00 EDT 2013},
month = {Tue Jun 11 00:00:00 EDT 2013}
}